Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 5.6% Today

What is Hims & Hers Health Inc.?

Hims & Hers Health (HIMS) operates as a telehealth company that specializes in offering personalized health and wellness products and services. The company's main focus is on delivering convenient and cost-effective healthcare solutions through its online platform.

Why is Hims & Hers Health Inc. going down?

HIMS stock is down 5.6% on Apr 28, 2026 13:45

• The initiation of a new stock repurchase plan worth up to $250 million by Hims & Hers Health potentially sparked initial investor optimism, resulting in a minor uptick in share prices.
• Subsequently, a series of notable insider selling activities conducted by the CFO and Chief Legal Officer may have triggered investor apprehensions regarding the company's future prospects, leading to a bearish trend in the stock.
• Factors such as the CFO's share sell-off, intensified competition from Amazon in the weight management industry, and uncertainties surrounding FDA regulations concerning peptides likely contributed to a prevailing negative outlook on HIMS stock, overshadowing the positive implications of the buyback initiative.

HIMS Price Chart

HIMS Technical Analysis

HIMS News

Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2%

Hims & Hers Health (HIMS) has announced a new stock buyback program, authorizing the repurchase of up to $250 million of its outstanding common stock. This initiative replaces a previous authorization from November 2023. Following the news, shares of the company rose approximately 2%.

http://www.msn.com/en-us/money/topstocks/hims-hers-health-effects-new-up-to-250m-stock-buyback-program-shares-up-2/ar-AA1QAHDi?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-t

Hims & Hers CFO Oluyemi Okupe sells $588,615 in Hims stock

Hims & Hers Health, Inc. CFO Oluyemi Okupe sold 19,645 shares of HIMS stock for $588,615 as part of a pre-arranged trading plan, while also acquiring 12,553 shares through option exercises. Following these transactions, Okupe directly holds 262,954 shares and indirectly holds 7,853 shares. The company has also seen recent developments related to Amazon's entry into weight management and FDA discussions on peptides, influencing analyst ratings.

https://m.investing.com/news/insider-trading-news/hims--hers-cfo-oluyemi-okupe-sells-588615-in-hims-stock-93CH-4630860?ampMode=1

Hims & Hers Health Legal Chief Sells Shares Worth Over $280000

Soleil Boughton, the Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), sold 9,463 shares of the company's Class A Common Stock for over $280,000 on April 20, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan, designed to prevent accusations of insider trading. Following the sale, Boughton still holds 299,368 shares in the telehealth company, with the filing providing transparency for investors.

https://www.koranmanado.co.id/en/hims-hers-legal-chief-stock-sale

Hims & Hers (NYSE: HIMS) CFO option exercises and pre-planned share sale

Hims & Hers Health CFO Oluyemi Okupe exercised stock options for 12,553 shares and subsequently sold 19,645 Class A Common Stock shares at an average price of $29.9626 under a pre-arranged Rule 10b5-1 trading plan. These transactions took place on April 20, 2026. Following these transactions, Okupe directly held 262,954 shares and indirectly held an additional 7,853 shares.

https://www.stocktitan.net/sec-filings/HIMS/form-4-hims-hers-health-inc-insider-trading-activity-a333733cc506.html

Hims & Hers CFO Oluyemi Okupe sells $588,615 in Hims stock

Oluyemi Okupe, the Chief Financial Officer of Hims & Hers Health, Inc. (NASDAQ: HIMS), sold 19,645 shares of the company's Class A Common Stock for $588,615 on April 20, 2026. This transaction was part of a pre-arranged trading plan, and on the same day, Okupe also acquired 12,553 shares through stock option exercises. The company has recently faced increased competition in weight management from Amazon, but also saw an uptick in shares following discussions around FDA's removal of certain peptide restrictions.

https://www.investing.com/news/insider-trading-news/hims--hers-cfo-oluyemi-okupe-sells-588615-in-hims-stock-93CH-4630860

Trending Today

Roku Inc. ($ROKU) Stock Forecast: Up 5.1% Today

Twilio Inc. Class A ($TWLO) Stock Forecast: Up 5.2% Today

eBay Inc. ($EBAY) Stock Forecast: Up 6.2% Today

Texas Instruments Incorporated ($TXN) Stock Forecast: Up 5.3% Today

Eli Lilly and Company ($LLY) Stock Forecast: Up 9.7% Today

Altria Group Inc. ($MO) Stock Forecast: Up 6.0% Today

Bristol-Myers Squibb Company ($BMY) Stock Forecast: Up 5.1% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 6.0% Today

O'Reilly Automotive Inc. ($ORLY) Stock Forecast: Up 8.7% Today

IPG Photonics Corporation ($IPGP) Stock Forecast: Up 5.4% Today

Hims & Hers Health Inc. Price History

07.03.2026 - HIMS Stock was down 5.1%

• HIMS stock displayed a significant downward trend today.
• Concerns among investors have been elevated by an investigation and lawsuit initiated by Kahn Swick & Foti, LLC, surrounding alleged misconduct by Hims & Hers Health, particularly in relation to its termination of partnership with Novo Nordisk.
• The negative market sentiment towards HIMS can be attributed to legal actions and regulatory scrutiny, including accusations of deceptive marketing and non-compliance with laws regarding compounded drugs.
• Despite potential growth prospects stemming from the Novo Nordisk partnership, uncertainties and legal issues faced by Hims & Hers Health have overshadowed the positive developments, leading to the downward movement in the market.

21.03.2026 - HIMS Stock was down 5.5%

• The decline in HIMS stock may be linked to the CFO, Okupe Oluyemi, who conducted substantial selling of company shares. This action potentially sparked apprehension among investors regarding the company's future performance.
• Market dynamics, such as upcoming FDA discussions concerning injectable peptides and heightened competition from Amazon Pharmacy, likely contributed to the pessimistic outlook on HIMS stock.
• Revised price projections by analysts from Leerink Partners and BofA Securities possibly impacted investor trust in the stock, leading to the decline.
• The varying performance of major indices in the market prompted instability in HIMS stock as investors reassessed their positions across different stocks, including Hims & Hers Health, Inc.

02.03.2026 - HIMS Stock was down 7.9%

• The stock of HIMS experienced a significant drop due to potential securities law violations and lawsuits related to the sale of compounded drugs, leading to investor concerns and a bearish sentiment.
• Despite a recent pullback, the company is trading at a discount to its intrinsic value and analyst price targets, indicating a lack of confidence in its future performance.
• The internal realignment by Vanguard, reporting 0 shares beneficially owned, might have added to the negative sentiment surrounding HIMS, signaling a lack of institutional support.
• The regulatory scrutiny and increased competition faced by Hims & Hers Health Inc. could further impact its stock price, highlighting the importance of monitoring price action for tactical trading decisions.

20.03.2026 - HIMS Stock was up 6.5%

• The insider sale notice of Class A shares by HIMS executives could have initially caused some uncertainty in the market.
• However, the overall positive sentiment towards HIMS, as highlighted by being on investors' radars alongside other notable companies like Microsoft and Tesla, likely contributed to the bullish movement.
• Investors might have been reassured by HIMS' strategic positioning in the telehealth industry and the potential for growth, especially in the current market environment focused on technology and healthcare sectors.

22.03.2026 - HIMS Stock was down 6.1%

• HIMS stock saw a decline today, which may be linked to substantial insider selling by the company's CFO, Okupe Oluyemi, who sold $1.46 million in company stock.
• A comparison between Hims & Hers and Amwell may have added to investor uncertainty, prompting a sell-off of HIMS stock as investors reassess their telehealth investments.
• Insider sales and executives' proposed sales of Class A shares could suggest a lack of confidence in the company's future, impacting investor sentiment and lowering the stock price.
• Despite potential growth opportunities such as upcoming FDA discussions and heightened competition, today's bearish movement in HIMS stock reflects investor caution amid ongoing market shifts and insider selling.

17.03.2026 - HIMS Stock was up 5.8%

• Hims & Hers stock exhibited bullish movement driven by positive sentiment surrounding the company. Factors contributing to this include:
• The significant gift of shares by the CEO, signaling confidence in the company's future and growth potential.
• Bullish sentiments expressed by analysts and traders on TradingView, supported by strong earnings and technical indicators, influencing increased investor interest.
• Positive market trends, reflected in gains seen in the S&P 500 and Nasdaq, likely also impacted HIMS stock.
• The company's emphasis on telehealth and personalized health products aligns with the current market demand for digital health solutions, further bolstering the bullish movement.
• Investor focus on Hims & Hers, alongside other prominent stocks like Microsoft and Tesla, indicates a broader interest in the technology and healthcare sectors, fueling positive momentum in the market.

08.03.2026 - HIMS Stock was down 5.5%

• The CFO's sale of shares and exercising of options may have signaled a lack of confidence in the company's future prospects, contributing to the bearish movement.
• The investigation initiated by a legal firm, and the investor lawsuit over alleged misconduct have likely raised concerns among investors, leading to a negative sentiment towards the stock.
• The termination of the partnership with another company and the allegations of deceptive marketing and failure to adhere to laws regarding compounded drugs have cast a shadow on Hims & Hers Health's reputation, impacting its stock performance negatively.
• The combination of insider selling, legal troubles, and ethical concerns has created a perfect storm of bad news for Hims & Hers Health, resulting in the bearish market movement observed today.

31.02.2026 - HIMS Stock was up 5.8%

• Despite recent challenges and regulatory scrutiny, Hims & Hers Health Inc. (HIMS) experienced a bullish movement with its stock today.
• The company's valuation, currently trading at a discount to its intrinsic value, is backed by fast revenue growth and increasing profitability.
• A prior investigation into potential securities law violations by a legal firm and FDA restrictions caused a significant stock pullback.
• Today's bullish sentiment may stem from renewed investor confidence in the company's long-term growth prospects and strategic actions to address regulatory concerns.

24.03.2026 - HIMS Stock was up 5.8%

• The bullish movement in HIMS stock today can be attributed to the positive sentiment generated by the Chief Legal Officer and Chief Financial Officer selling shares worth over $280,000 and $588,615 respectively. This could indicate confidence in the company's future performance.
• The uptick in shares following discussions around FDA's removal of certain peptide restrictions might have also contributed to the bullish movement, showing potential growth opportunities for the company in the healthcare sector.
• Comparisons between Hims & Hers and Amwell might have sparked investor interest in HIMS, positioning it favorably against its competitors in the telehealth industry.

28.03.2026 - HIMS Stock was down 5.6%

• The initiation of a new stock repurchase plan worth up to $250 million by Hims & Hers Health potentially sparked initial investor optimism, resulting in a minor uptick in share prices.
• Subsequently, a series of notable insider selling activities conducted by the CFO and Chief Legal Officer may have triggered investor apprehensions regarding the company's future prospects, leading to a bearish trend in the stock.
• Factors such as the CFO's share sell-off, intensified competition from Amazon in the weight management industry, and uncertainties surrounding FDA regulations concerning peptides likely contributed to a prevailing negative outlook on HIMS stock, overshadowing the positive implications of the buyback initiative.

13.03.2026 - HIMS Stock was up 5.5%

• The CEO's generous donation of 845,866 shares of Class A Common Stock may have reassured investors, indicating a steadfast dedication to the company's growth and prosperity.
• Despite a 6.1% decrease following an expansion in GLP-1 access through a partnership with Novo Nordisk, this development could be perceived as a strategic move to enhance the company's offerings in medically supervised weight management.
• The ongoing fraud investigation by the Schall Law Firm might have initially caused uncertainty, leading to a decline in share prices. Nevertheless, today's bullish trend suggests that investors may hold a positive outlook on the company's ability to address these legal issues effectively.
• Various discussions about technical analysis and trade opportunities might have influenced the optimism, as traders could identify potential long positions based on strong earnings and technical signals.

27.02.2026 - HIMS Stock was down 5.1%

• Today's bearish movement in HIMS stock may be linked to an ongoing investigation into potential securities law violations related to compounded GLP-1 active pharmaceutical ingredients by the Schall Law Firm, and a lawsuit from Novo Nordisk concerning the sale of compounded weight loss drugs.
• The CFO of Hims & Hers Health, Oluyemi Okupe, engaged in insider trading by selling a substantial amount of shares, possibly contributing to the negative market sentiment.
• Despite recent positive developments such as partnerships and the renewal of the weight loss drug partnership with Novo Nordisk, analysts have noted concerns about the stock's valuation, suggesting it may be undervalued compared to its current price. This perceived disparity could be a factor fueling the sell-off in the stock.